Lamotrigine 200 mg: What This Dose Means and Why It Is the Target
Author:
Blossom Editorial
Lamotrigine 200 mg is the standard target dose for maintenance treatment of bipolar I disorder in adults who are not taking medications that substantially affect lamotrigine levels.
If you have been slowly working up from 25 mg over several weeks, reaching 200 mg usually means you have arrived at the dose the medication was studied at, not that you are on a high dose. Understanding where 200 mg sits in the dosing range, and what can shift that number, makes the titration process far less confusing.
Key Takeaways
200 mg is the target, not the ceiling: FDA labeling identifies 200 mg per day as the target maintenance dose for bipolar I disorder in adults not taking interacting medications, and reaching it typically takes about six weeks of gradual titration. The maximum dose studied in clinical trials of lamotrigine is 400 mg.
Your target may not be 200 mg: People taking valproate usually target 100 mg per day, while people taking certain enzyme-inducing medications may target 400 mg per day, because those drugs change how quickly lamotrigine is cleared.
The slow start is a safety measure: Titration is deliberately gradual to reduce the risk of serious rash, and exceeding the recommended starting dose or escalation rate increases that risk.
What is Lamotrigine 200 mg Used For?
Lamotrigine, sold under the brand name Lamictal, is an anticonvulsant that is also FDA-approved for maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes. It belongs to a category of bipolar medications called mood stabilizers. Lamotrigine is also indicatedfor adjunctive or conversion-to-monotherapy treatment for several seizure types.
The labeling specifies that lamotrigine is not recommended for acute manic or mixed episodes, and its effectiveness in the acute treatment of mood episodes has not been established. Its role is preventive. However, clinical guidelines may recommend lamotrigine in some cases of bipolar depression, and clinicians may also use it off-label depending on a person's symptoms and treatment history..
Tablets come in 25 mg, 100 mg, 150 mg, and 200 mg strengths, all scored, while orally disintegrating tablets are available in 25 mg, 50 mg, 100 mg, and 200 mg.
Why 200 mg is the Target Dose for Bipolar Disorder
The 200 mg figure is based on clinical trials that established lamotrigine as a maintenance treatment for bipolar 1 disorder. However, the target dose may be different for you depending on what other medications you take.
200 mg as the Standard Monotherapy Target
For adults not taking valproate or an enzyme-inducing medication, FDA labeling sets the target at 200 mg per day. Although trials evaluated doses up to 400 mg per day as monotherapy, no additional benefit was seen at these higher doses compared with 200 mg. Therefore, 200 mg is usually a target dose for adults who are not taking medications that substantially alter lamotrigine levels.
Two 18-month, placebo-controlled trials formed the basis for that conclusion. In a 2003 trial published in the Journal of Clinical Psychiatry enrolling recently depressed patients, lamotrigine was titrated to 200 mg per day during the open-label phase, and both lamotrigine and lithium significantly prolonged the time to intervention for a mood episode compared with placebo. The time to intervention for any mood episode for lamotrigine was 200 days, while that for lithium was 170 days. Moreover, 57% of patients on lamotrigine remained intervention-free for depression at one year, compared to 46% of people on lithium.
A similar study published the same year in the Archives of General Psychiatry on patients with a recent history of mania and hypomania in bipolar 1 showed lamotrigine superior to placebo at increasing the intervention time for a depressive episode. The same study also showed that lithium was superior to placebo at increasing the time to intervention for a manic, hypomanic, or mixed episode.
A pooled analysis of these two studies covered 1,315 patients and found lamotrigine effective against depression and mania, with a predominant effect on depression, while lithium was primarily effective against mania.
100 mg When Taking Valproate
Valproate (Depakote) is an anti-seizure medication and mood stabilizer used to treat active mania. Some people on valproate may be prescribed lithium or lamotrigine as combination treatment. However, valproate inhibits the enzyme that clears lamotrigine and raises lamotrigine concentrations by slightly more than twofold. For that reason, the target dose of lamotrigine for people taking valproate is 100 mg per day, roughly half the usual amount, and the titration schedule starts at 25 mg every other day rather than 25 mg daily.
400 mg With Enzyme-Inducing Medications
The anti-convulsant and mood stabilizer carbamazepine; anti-seizure medications, including phenytoin, phenobarbital, and primidone; the antibiotic rifampin; and protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir speed up lamotrigine clearance and lower its concentration in the blood.
When one of these is prescribed without valproate, the target dose of lamotrigine rises to 400 mg per day. The starting dose in such cases begins at 50 mg daily.
How Long It Takes to Reach Lamotrigine 200 mg
The path to 200 mg is deliberately slow. The table below shows the labeled escalation schedule for adults with bipolar disorder who are not taking valproate or an enzyme-inducing medication.
Weeks | Daily dose of lamotrigine |
|---|---|
Weeks 1 and 2 | 25 mg |
Weeks 3 and 4 | 50 mg |
Week 5 | 100 mg |
Week 6 onward | 200 mg |
That puts most people at 200 mg around week six. Starter kits are available for the first five weeks to help people follow the schedule correctly, and the labeling explains why this is crucial: exceeding the recommended initial dose or escalation rate increases the risk of serious rashes, including a rare but life-threatening reaction called Stevens-Johnson syndrome.
If lamotrigine is stopped for longer than about five half-lives, contact your prescriber before restarting at the last dose. Depending on how long you have been off the medication and what other medications you take, you may need to restart with a lower dose and repeat part or all of the titration schedule.
Lamotrigine 200 mg in Epilepsy
The 200 mg dose means something different in epilepsy, where maintenance ranges are generally higher. According to the FDA labeling, for adults on adjunctive lamotrigine with valproate alone, the usual maintenance range is 100 to 200 mg per day, so 200 mg sits at the top of that range.
For patients not taking valproate or enzyme inducers, usual adjunctive maintenance is 225 to 375 mg per day, and for those on enzyme-inducing drugs it is 300 to 500 mg per day, both in divided doses. Epilepsy monotherapy is 500 mg per day in two divided doses. In that context, 200 mg is a waypoint rather than a destination.
Side Effects at Lamotrigine 200 mg
In the two 18-month bipolar trials, adverse reactions reported by more than 5% of adults taking lamotrigine at 100 to 400 mg per day included nausea, insomnia, somnolence, back pain, fatigue, rash, rhinitis, abdominal pain, and dry mouth. Rates were often close to placebo: nausea occurred in 14% on lamotrigine versus 11% on placebo, insomnia in 10% versus 6 percent, and fatigue in 8% versus 5%. Some people also experience vomiting and constipation.
Other effects worth knowing about include:
Dizziness, blurred vision, or double vision: Reported for epilepsy dosing (300 to 500 mg) in an adjunctive trial and generally dose-related.
Headache, rash, dizziness, diarrhea: Frequently reported during the dose-escalation phase in the bipolar trials.
Coordination or balance changes: More likely if levels rise because of an interaction; can also occur during epilepsy monotherapy
Mood or behavior changes: Anticonvulsants carry a warning about suicidal thoughts or behavior, and monitoring is recommended for any indication.
Lamotrigine carries the class warning applied to antiseizure medications regarding suicidal thoughts or behavior. The warning is based on a pooled FDA analysis of placebo-controlled trials involving multiple antiseizure medications and indications, rather than a risk estimate specific to lamotrigine alone. Patients and caregivers should watch for new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior.
The Rash Warning at Any Lamotrigine Dose
Lamotrigine carries a boxed warning for serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis. This is the most important thing to understand about the medication.
The risk is highest early in treatment, particularly during the first several weeks and when recommended starting doses or escalation schedules are exceeded. However, serious rashes can occasionally occur later, so a new rash should always be taken seriously. Because benign rashes also occur and it is not possible to predict which ones will become serious, labeling advises discontinuing lamotrigine at the first sign of rash unless it is clearly unrelated. Any new rash warrants same-day contact with a prescriber.
In premarketing bipolar and mood disorder trials, serious rash requiring hospitalization occurred in 0.08%of adults receiving lamotrigine as initial monotherapy and 0.13% receiving it as adjunctive therapy. In adult epilepsy trials, the rate was 0.3%, and rates are higher in pediatric patients.
What Can Change Your Lamotrigine 200 mg Dose
A stable 200 mg dose is not necessarily permanent, and several common changes can require an adjustment:
Starting or stopping estrogen-containing contraceptives: These lower lamotrigine concentrations by roughly 50%, and the maintenance dose may need to increase by as much as twofold when starting one, or decrease when stopping. Dose changes must be individualized by the prescriber.
Adding or removing valproate: Introducing valproate requires a dose reduction, while discontinuing it could require roughly doubling the lamotrigine dose over two weeks in equal increments.
Adding or removing an enzyme inducer: Carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, and atazanavir/ritonavir all shift levels meaningfully. Adding them necessitates a gradual dose increase of lamotrigine up to 400 mg. Discontinuing would require a gradual step down by half over a two-week period.
Pregnancy: Pregnancy can increase clearance and lower blood concentrations, while clearance can decrease again after delivery, causing levels to rise. Some patients need dose adjustments during pregnancy and again postpartum, so management should be individualized with the prescribing clinician and obstetric care team.
Liver impairment: Doses are generally reduced by about 25% in moderate to severe impairment without ascites, and about 50% in severe impairment with ascites. Further dose adjustment may be made by the prescriber depending on clinical response.
Stopping the medication: Lamotrigine should be tapered over at least two weeks, at roughly 50% per week, rather than stopped abruptly.
Labeling also recommends that people taking lamotrigine for maintenance treatment for more than 16 weeks be periodically reassessed. That check-in is a normal part of care.
When to Seek Medical Attention
Contact your healthcare provider immediately for:
A new rash
Fever or swollen lymph nodes
Mouth or eye sores
Unusual bruising or bleeding
Frequent infections
Dizziness, double vision, or unsteadiness that is new or getting worse
New or worsening depression or unusual changes in mood or behavior
Seek emergency medical care for severe symptoms such as:
Blistering or peeling skin
A rapidly spreading rash
Severe swelling of the face, lips, or tongue
Difficulty breathing
Severe systemic illness
Seek emergency care for a spreading rash with blistering or peeling skin. If you are having thoughts of suicide, call or text 988 to reach the Suicide and Crisis Lifeline. If you are in immediate danger, call 911 or go to the nearest emergency department.
How Blossom Health Can Help
Getting to a stable lamotrigine dose takes weeks of structured titration and regular check-ins, and it is easier when you can virtually visit your prescriber. Blossom Health is a telehealth psychiatry practice where every provider is a licensed prescriber, so titration questions, side effect concerns, and refills all run through the same clinician, from the comfort of your home.
If you are not sure whether your symptoms warrant specialty care, our guide on when to see a psychiatrist covers the common signs.
Care is virtual and covered by in-network insurance, and appointments are typically available within days. You can get started here.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or medication. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Sources
FDA Prescribing Information. (March, 2015). Lamictal (Lamotrigine). https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020241s045s051lbl.pdf
U.S. Food and Drug Administration. (2025). Lamictal XR (lamotrigine) extended-release tablets, for oral use: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022115s033s034lbl.pdf
Betchel NT, Fariba KA, Saadabadi A. Lamotrigine. [Updated 2023 Feb 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470442/
Nath M, Patel P. Mood Stabilizers. [Updated 2026 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556141/
Subbarao BS, Silverman A, Eapen BC. Seizure Medications. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482269/
Calabrese, J. R., Bowden, C. L., Sachs, G., Lamictal 605 Study Group, et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. The Journal of clinical psychiatry, 64(9), 1013–1024. https://pubmed.ncbi.nlm.nih.gov/14628976/
Bowden, C. L., Calabrese, J. R., Sachs, G., Lamictal 606 Study Group, et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of general psychiatry, 60(4), 392–400. https://pubmed.ncbi.nlm.nih.gov/12695317/
Goodwin, G. M., Bowden, C. L., Calabrese, J. R., et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. The Journal of clinical psychiatry, 65(3), 432–441. https://pubmed.ncbi.nlm.nih.gov/15096085/
National Institute of Mental Health. (2023, December). Mental health medications. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/mental-health-medications
